You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

diffuse large B-cell lymphoma (DLBCL)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:

Completed
  • Diffuse Large B-cell Lymphoma
    • East Hanover, New Jersey
      Novartis
    Jun 16, 2023

    Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

    Recruiting
    • Diffuse Large B Cell Lymphoma，DLBCL
    • PM 8.4 mg/m2
    • PM 11.2 mg/m2
    • Chengdu, Sichuan, China
      West China Hospital Sichuan University
    Jan 15, 2023

    DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma Trial in Shanghai (Other)

    Not yet recruiting
    • DLBCL - Diffuse Large B Cell Lymphoma
    • Lymphoma
    • Other
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Sep 6, 2023

    Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma (DLBCL)
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Sep 18, 2023

    Diffuse Large B Cell Lymphoma Trial in Tampa (Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Itacitinib
    • Chimeric antigen receptor (CAR) T-cell therapy
    • Tampa, Florida
      Moffitt Cancer Center
    Mar 6, 2023

    Diffuse Large B-cell Lymphoma (DLBCL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)

    Recruiting
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • Westbury, New York
      Clinical Research Alliance Inc
    Oct 13, 2023

    Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma

    Completed
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • CAR-T
    • Allo-HSCT cohort
    • East Hanover, New Jersey
      Novartis Investigative Site
    Jun 29, 2022

    Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • (no location specified)
    Mar 23, 2023

    Non Hodgkin Lymphoma Trial in United Kingdom (R-CHOP + acalabrutinib)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • R-CHOP + acalabrutinib
    • Southampton, Hampshire, United Kingdom
    • +6 more
    Oct 26, 2022

    Non-GCB/ABC DLBCL, With and Without MyD88 and/or CD79B Mutations Trial in Cleveland, Toledo (Mivavotinib)

    Recruiting
    • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
    • With and Without MyD88 and/or CD79B Mutations
    • Evanston, Illinois
    • +6 more
    Dec 12, 2022

    Diffuse Large B-cell Lymphoma (DLBCL) Trial in Lanzhou (Zanubrutinib)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • Lanzhou, Gansu, China
      The First Hospital of Lanzhou University
    Oct 23, 2022

    Lymphomas Non-Hodgkin's B-Cell Trial in Ballarat, Box Hill, Heidelberg (Avelumab)

    Active, not recruiting
    • Lymphomas Non-Hodgkin's B-Cell
    • Ballarat, Victoria, Australia
    • +2 more
    Jan 30, 2023

    Diffuse Large B Cell Lymphoma (DLBCL) Trial in Shanghai (Orelabrutinib + R-CHOP, Placebo + R-CHOP)

    Recruiting
    • Diffuse Large B Cell Lymphoma (DLBCL)
    • Orelabrutinib + R-CHOP
    • Placebo + R-CHOP
    • Shanghai, Shanghai, China
      Shanghai Ruijing Hospital
    Nov 28, 2022

    Relapsed or Refractory (R/R) Follicular Lymphoma (FL), DLBCL (DLBCL) Trial (Odronextamab)

    Available
    • Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
    • Diffuse Large B-Cell Lymphoma (DLBCL)
    • (no location specified)
    Nov 8, 2022

    DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

    Recruiting
    • DLBCL
    • +3 more
    • Minneapolis, Minnesota
      University of Minnesota, Masonic Cancer Center
    Jul 1, 2022

    Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

    Suspended
    • Burkitt Lymphoma
    • +4 more
    • Rituximab
    • +6 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    Diffuse Large B-cell Lymphoma (DLBCL) Trial in Münster (L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab)

    Active, not recruiting
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • L19-IL2 - Ph I
    • +2 more
    • Münster, Germany
      Münster University Hospital
    Apr 19, 2022

    Diffuse Large B-cell Lymphoma (DLBCL) Trial in China (abexinostat)

    Recruiting
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • Beijing, China
    • +22 more
    Jan 26, 2023

    Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial (Routine care as per

    Not yet recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • +5 more
    • Routine care as per site standard.
    • (no location specified)
    Sep 15, 2023

    Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)

    Recruiting
    • Large B-cell Lymphoma
    • DLBCL
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Oct 3, 2022

    Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

    Recruiting
    • Diffuse Large B-cell Lymphoma Recurrent
    • Diffuse Large B Cell Lymphoma Refractory
    • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Oct 12, 2023

    Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

    Recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • +6 more
    • Beijing, China
      Beijing Cancer Hospital
    Feb 6, 2023

    DLBCL Trial in Seoul (Tislelizumab, Pemetrexed)

    Not yet recruiting
    • DLBCL
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Feb 15, 2022

    DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)

    Active, not recruiting
    • Diffuse Large B-Cell Lymphoma (DLBCL)
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023